Quinn 2012*.

Methods	Allocation: random. Blinding: open‐label. Duration: 24 months. Design: parallel. Setting: multi‐centre, Canada.
Participants	Diagnosis: schizophrenia, schizophreniform disorder or schizoaffective disorder (DSM‐IV). N = 85. Age: risperidone depot mean 22.5 +/‐ 3.12 years of age; oral SGA mean 23.0 +/‐ 2.93 years of age. Sex: 65 M, 12 F. History: early onset (within the past 3 years) of psychosis. Included: no inclusion criteria stated. Excluded: no exclusion criteria stated. Consent: no details.
Interventions	1. Risperidone depot: every 2 weeks, median dose at 18 weeks 25 mg; at 9, 12 and final visit 37.5 mg, n = 45. 2. Oral second generation antipsychotics (risperidone, olanzapine or quetiapine) (dosage not specified), n = 40.
Outcomes	Leaving the study early (discontinuation). Global state (relapse). Specific adverse events. Unable to use ‐ Mental state: PANSS; Global state: CGI‐S; Anxiety: Hamilton Anxiety scale; SAFS (unclear as to participant numbers within groups). Time to stabilisation (no SD).
Notes	Note: extractable data limited due to only available results from this study derived from conference poster.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote, "patients were randomized" ‐ no further details.
Allocation concealment (selection bias)	Unclear risk	Not described.
Blinding (performance bias and detection bias) All outcomes	High risk	Open‐label described ‐ no further details.
Incomplete outcome data (attrition bias) All outcomes	High risk	N = 46 (54%) discontinued the study;
Selective reporting (reporting bias)	Unclear risk	Conference poster, therefore results for all outcomes were not provided.
Other bias	High risk	Quinn AM and Mitchell D are both employees of Janssen Inc and Johnson and Johnson Stockholders; Camacho F is consultant to Janssen Inc; Chue P has received research and travel grants from Janssen, Pfizer, Eli Lilly, AstraZeneca, Sunovion, Lundbeck, GlaxoSmithKline, Bristol Mayers Squibb, Mylan, Novartis and Hoffman La Roche, Mella.